Abstract
The National Cancer Institute since 1955 has been charged with responsibility for discovering new anti-cancer agents and bringing them to clinical trial. These activities are carried out by NCI's Developmental Therapeutics Program, which has established systems for discovery, experimental testing, bulk synthesis, formulation, and toxicological testing of candidate drugs, and by the Cancer Therapy Evaluation Program, which conducts initial trials to establish safe doses of new agents and to determine their utility in treating specific forms of cancer. These clinical trials are conducted both at NCI in Bethesda, Md., and at selected cancer centers throughout the United States. This paper describes the safeguards that NCI has built into the clinical trials system in the past decade-safeguards that ensure the safety of patients and the accuracy of data collected and at the same time allow efficient testing of each promising new agent in the fight against cancer. Recent improvements in cancer survival leave little doubt that patients are indeed benefiting from extensive efforts to discover and develop new drugs for cancer treatment.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anderson G., Peel E. T., Cheong C. M., Broderick N. J. Etoposide--an effective single drug for treating bronchogenic carcinoma. Clin Oncol. 1982;8(3):215–218. [PubMed] [Google Scholar]
- Driscoll J. S. The preclinical new drug research program of the National Cancer Institute. Cancer Treat Rep. 1984 Jan;68(1):63–76. [PubMed] [Google Scholar]
- Hodes L. Selection of molecular fragment features for structure-activity studies in antitumor screening. J Chem Inf Comput Sci. 1981 Aug;21(3):132–136. doi: 10.1021/ci00031a004. [DOI] [PubMed] [Google Scholar]
- Legha S. S., Keating M. J., McCredie K. B., Bodey G. P., Freireich E. J. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. Blood. 1982 Aug;60(2):484–490. [PubMed] [Google Scholar]
- Ley T. J., DeSimone J., Anagnou N. P., Keller G. H., Humphries R. K., Turner P. H., Young N. S., Keller P., Nienhuis A. W. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med. 1982 Dec 9;307(24):1469–1475. doi: 10.1056/NEJM198212093072401. [DOI] [PubMed] [Google Scholar]
- Prentice H. G., Smyth J. F., Ganeshaguru K., Wonke B., Bradstock K. F., Janossy G., Goldstone A. H., Hoffbrand A. V. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia. Lancet. 1980 Jul 26;2(8187):170–172. doi: 10.1016/s0140-6736(80)90060-4. [DOI] [PubMed] [Google Scholar]
- Taylor R. E., McElwain T. J., Barrett A., Peckham M. J. Etoposide as a single agent in relapsed advanced lymphomas. A phase II study. Cancer Chemother Pharmacol. 1982;7(2-3):175–177. doi: 10.1007/BF00254543. [DOI] [PubMed] [Google Scholar]
- Yap H. Y., Blumenschein G. R., Schell F. C., Buzdar A. U., Valdivieso M., Bodey G. P. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med. 1981 Dec;95(6):694–697. doi: 10.7326/0003-4819-95-6-694. [DOI] [PubMed] [Google Scholar]